Intellectual Property In India: Novartis Gleevec Patent Battle Will Go On Without Government Document Supporting “Evergreening” (Part 1 of 3)

In the first part of a three-part series on difficulties faced by drug manufacturers in patenting products in India, “The Pink Sheet” DAILY looks at the uphill battle Novartis faces in its lawsuit against the government to obtain a patent for a new formulation of Gleevec.